Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: A secondary analysis using centers for medicare & medicaid services data

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 12, 2009, Pages 1954-1961

  St Peter, Wendy L ^a,b   Fan, Qiao ^a   Weinhandl, Eric ^a   Liu, Jiannong ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; ELIPHOS; SEVELAMER; TUMS; TUMS ULTRA; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS;

ACETATES; CALCIUM CARBONATE; CALCIUM COMPOUNDS; CHELATING AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MEDICAID; MEDICARE; PHOSPHATES; POLYAMINES; RENAL DIALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 73649119160     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04100609     Document Type: Article

References (19)

1. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-201, 2003
2. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
3. Collins AJ, Li S, St Peter WL, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
4. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007
5. St Peter WL, Liu J, Weinhandl ED, Fan Q: Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodial Int 12: 480-491, 2008
6. St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51: 445-454, 2008
7. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M: Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878, 2007
8. Medispan: PriceChek PC®: A drug database by MediSpan (Indianapolis, IN), a division of Wolters Kluwer Health, Inc., based on archived and current data as of July 1, 2009. Available at http://www.medispan.com/index.aspx. Accessed September 14, 2009
9. Collins AJ, Li S, Ebben J, Ma JZ, Manning W: Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36: 282-293, 2000
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617, 1998
11. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396, 2009
12. U.S. Renal Data System: 2007 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
13. St Peter WL: Potential impact of Medicare Part D in the end-stage renal disease population. Adv Chronic Kidney Dis 15: 140-146, 2008
14. Kidney Medicare Drugs Awareness and Education Initiative: Changing formularies over time. Available at: http://www.kidneydrugcoverage.org/pdf/ ChangesinFormulariesOverTime11-15-07.pdf. Accessed September 14, 2009
15. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 8: 549-561, 2005
16. Huybrechts KF, Caro JJ, London GM: Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 67: 1532-1538, 2005
17. Tomasello S, Dhupar S, Sherman RA: Phosphate binders, K/DOQI guidelines, and compliance: The unfortunate reality. Dial Transplant 33: 236-240, 2004
18. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4: 1089-1096, 2009
19. U.S. Renal Data System: 2008 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008